HRS-4642 plus AG before and after surgery for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of two medications (HRS-4642 and AG) given before and after surgery for pancreatic cancer that can be removed. The goal is to see if this treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your pancreatic cancer is diagnosed as ductal adenocarcinoma and can be removed with surgery (either resectable or borderline resectable).
- You have not had any previous treatment for this cancer (like chemotherapy or radiation).
- Your cancer has not spread to other organs (no distant metastases).
- You are generally well enough to do daily activities without help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
This trial tests a new drug combination given before surgery for pancreatic cancer that has not spread. It includes targeted therapy, chemotherapy, and possibly immunotherapy to see if it can shrink tumors and improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.